Device repurposes cells, healing organs without additional treatment

Described in the recent issue of Nature Nanotechnology, a technology called Tissue Nanotransfection (TNT) technology has shown an ability to transform skin cells into other types of cells with 98 percent accuracy, with the potential ability to save failing organs.

A chip device is loaded with specific genetic codes or proteins and releases an electrical current when placed against the skin where it injects DNA or RNA and reprograms the cells. In lab tests on vascular veins in mice, the chip could show a change in cells at one week. By the second week, active blood vessels began to form. The legs in the mice were treated by the third week.

“It takes just a fraction of a second. You simply touch the chip to the wounded area, then remove it,” said Chandan Sen, PhD, director of the Center for Regenerative Medicine and Cell-Based Therapies at The Ohio State University Wexner Medical Center. “At that point, the cell reprogramming begins.”

In clinical tests done on the device, researchers noted it could achieve 98 percent efficiency. Researchers hope that the chip can be used on other cells than just skin cells. In tests done on the brain cells of mice, researchers were able to harvest and inject the cells back into the brain after having a stroke. In a few weeks, the brain could regain function and was healed.

“It extends the concept known as gene therapy, and it has been around for quite some time,” said study collaborator James Lee, PhD, a professor of chemical and biomolecular engineering at Ohio State. “The difference with our technology is how we deliver the DNA into the cells.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”